转氨基粉症治疗的进展
相关实验视频
Updated: Sep 14, 2025

06:33
Genetic Analysis of Hereditary Transthyretin Ala97Ser Related Amyloidosis
Published on: June 9, 2018
7.8K
1Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden.
eGastroenterology
|July 23, 2025
概括
本综述涵盖了当前和新兴的治疗Transthyretin Amyloidosis (ATTR) 的方法,重点关注神经病和心脏症状. 诊断和治疗方面的进步正在改善这种严重疾病的早期发现和管理.
科学领域:
- 心脏病学 心脏病学
- 神经学 神经学
- 遗传学 是一个遗传学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 晶氨基粉症 (ATTR) 是一种进展性,危及生命的疾病,影响心脏和神经.
- 在历史上被诊断不足,ATTR诊断正在通过先进的非侵入性技术得到改善.
- 神经病和心脏表现显著影响患者的生活质量.
研究的目的:
- 为ATTR提供当前和研究中的治疗方法的全面概述.
- 讨论管理ATTR心脏和神经病症状的新兴策略.
- 突出改善诊断对早期干预的影响.
主要方法:
- 对ATTR疗法的现有文献的综述.
- 对新型ATTR治疗方法正在进行的临床试验的分析.
- 讨论ATTR检测中的诊断进展.
主要成果:
- 有几种治疗策略可用并且正在开发中,包括四聚体稳定,基因沉默和纤维细胞破坏/去除.
- 通过新技术促进的早期诊断提高了治疗的有效性.
- 改变疾病的治疗方法正在改变ATTR管理.
结论:
- 现在可以获得有效的ATTR治疗方法,并且正在开发中.
- 早期诊断和及时开始治疗对于管理ATTR至关重要.
- 目前正在进行的研究有望在打击ATTR方面取得进一步进展.
相关概念视频
Alzheimer's Disease: Treatment
262
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
262
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
226
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
226
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
260
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
260
Heart Failure VI: Adjunct Therapies
29
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
29
Cardiomyopathy V: Interprofessional Care
35
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
35
Atherosclerosis III: Management
36
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
36

